Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
EY US & Bayer Win “Artificial Intelligence for Good” Award in 2025 AI Breakthrough Awards Program
10:00am, Wednesday, 25'th Jun 2025
Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions
Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane
11:56am, Wednesday, 18'th Jun 2025
BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.
Bayer Files for Approval of gadoquatrane in the U.S.
11:00am, Tuesday, 17'th Jun 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane f
Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients
03:30am, Tuesday, 17'th Jun 2025
Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been sele
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
10:11am, Monday, 16'th Jun 2025
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Bayer Innovation Procurement Expands Use of Scientist.com's AI-Powered Platform for Global R&D Procurement Orchestration
07:55am, Monday, 16'th Jun 2025
SAN DIEGO--(BUSINESS WIRE)-- #innovation--Bayer AG Innovation Procurement names Scientist.com as preferred global channel for sourcing external R&D services.
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
02:30am, Wednesday, 11'th Jun 2025
BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advan
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
08:00am, Wednesday, 04'th Jun 2025
SAN DIEGO & BERLIN, Germany--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG,
Airlines must ink long-term deals on greener fuels to boost volumes: Bayer exec
04:43pm, Tuesday, 03'rd Jun 2025
Airlines need to reach long-term agreements to buy bigger quantities of sustainable aviation fuel if they want to boost global volumes of the lower-emission fuel required for industry climate targets,
Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress
06:00am, Tuesday, 03'rd Jun 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Co
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
10:46am, Wednesday, 28'th May 2025
Here is how Bayer Aktiengesellschaft (BAYRY) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
11:06am, Friday, 23'rd May 2025
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals
02:58am, Friday, 23'rd May 2025
German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche'
Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development
10:58am, Thursday, 22'nd May 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical tr
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
01:36pm, Wednesday, 21'st May 2025
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
